Evidence map›Paper›PMID 42334193›Full record

ArticleJournal of medicinal chemistry2026

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Lingying Leng, Liyue Huang, Wenbin Tu, Wei Jiang, Rohan Kalyan Rej, Srinivasa Rao Allu, Yu Wang, Mi Wang, Jelena Tošović, Meilin Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lingying LengDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Liyue HuangDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Wenbin TuDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Wei JiangDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Rohan Kalyan RejDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0003-0904-9137
Srinivasa Rao AlluDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Yu WangDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Mi WangDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.
Jelena TošovićDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0001-5531-7193
Meilin WangDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Bo WenDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.
Duxin SunDepartment of Pharmaceutical Sciences, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-6406-2126
Shaomeng WangDepartment of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48109, United States.ORCID 0000-0002-8782-6950

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
NCI NIH HHS P30 CA046592
6 · The paper itself

Abstract

Selective targeting SMARCA2 by degradation represents a promising new therapeutic strategy for human cancers harboring deficient SMARCA4. Herein we report the discovery of highly potent, selective and oral available SMARCA2 PROTAC degraders, as exemplified by SMD-6346. SMD-6346 achieves DC

Indexed as

Antineoplastic AgentsDNA HelicasesDrug DiscoveryNeoplasmsNuclear ProteinsTranscription FactorsAdministration, OralAnimalsCell Line, TumorCell ProliferationFemaleHumansMiceProteolysis Targeting ChimeraStructure-Activity RelationshipXenograft Model Antitumor AssaysAntineoplastic AgentsDNA HelicasesNuclear ProteinsProteolysis Targeting ChimeraSMARCA2 protein, humanSMARCA4 protein, humanTranscription Factors

Identifiers

PMID42334193
PMCPMC13371081

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.